Drug-Drug Interaction Study of ABP-671 in Gout Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.